Watching Shares Of GSK; UBS Note Says ACIP Working Group Recommends Universal RSV Vaccine for Age 75+ From SCD; No Endorsement for Ages 50-59 Due to Limited Data; 60-74 Recommendation Only for "At Risk"
Watching Shares Of GSK; UBS Note Says ACIP Working Group Recommends Universal RSV Vaccine for Age 75+ From SCD; No Endorsement for Ages 50-59 Due to Limited Data; 60-74 Recommendation Only for "At Risk"
正在關注GSK股票，UBS報告稱ACIP工作組推薦針對75歲以上SCD人群接種全面RSV生物-疫苗；由於數據有限，對50到59歲的人群未給予認可；對於“有風險”的60到74歲人群只推薦接種。
Watching Shares Of GSK; UBS Note Says ACIP Working Group Recommends Universal RSV Vaccine for Age 75+ From SCD; No Endorsement for Ages 50-59 Due to Limited Data; 60-74 Recommendation Only for "At Risk"
正在關注GSK股票，UBS報告稱ACIP工作組推薦針對75歲以上SCD人群接種全面RSV生物-疫苗；由於數據有限，對50到59歲的人群未給予認可；對於“有風險”的60到74歲人群只推薦接種。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。